News Releases

 

BioSante Featured on the Med Tech Sentinal

Lincolnshire, Illinois (February 8, 2010) – BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) President and CEO Stephen M. Simes, was interviewed for “Med Tech Sentinel” and featured on its website.

Program host Bill Dawson interviewed Mr. Simes regarding the development program for LibiGel® (testosterone gel), now in Phase III safety and efficacy trials, and on BioSante financial condition and upcoming milestones.

Med Tech Sentinel is a feature of OneMedPlace (OMP), a virtual community for those involved in health and medical innovations. It is a portal to information needed by strategic and financial investors and has a database of more than 7,000 companies.

About BioSante Pharmaceuticals, Inc.

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante’s lead products include LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin™ (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S. Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals (NASDAQ: TEVA) and an oral contraceptive in Phase II clinical development using BioSante patented technology.

The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3 billion. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), as a vaccine adjuvant, including for an H1N1 (swine flu) vaccine, and drug delivery. In addition, BioSante will seek opportunities for its GVAX cancer immunotherapies, 2A/Furin and other technologies. Additional information is available online at: biosantepharma.cdmail.biz.

###

For more information please contact:

For Media:
Harris D. McKinney, Inc.
Alan Zachary
(312) 506-5220
azachary@harrisdmckinney.com